An experimental tuberculosis vaccine designed to improve on the century-old BCG shot did not prove as good as BCG at preventing tuberculosis infection in newborns, according to one of the largest infant tuberculosis vaccine trials ever run.
The phase 3 priMe trial tested VPM1002, a genetically modified version of BCG, against the standard vaccine at ten main sites and four satellite sites across sub-Saharan Africa. Results were published in The Lancet Infectious Diseases and covered in the infectious disease trade press.
